Juliet French

Congratulations Eduardo!!

Individuals with the 3p26 risk-haplotype have reduced BRRIAR, resulting in i) attenuated ISG transcription and increased tumor cell proliferation and ii) impaired RIG-I activation and Type I/III IFN signaling, fostering a more immunosuppressive TME that favors ER + breast tumor development.

In the cytoplasm, the BRRIAR lnRNA binds to and primes the cytosolic pattern recognition receptor, RIG-I, leading to increased TypeI/III Interferon signaling/production. Knockdown of BRRIAR inhibits RIG-I activation by other RIG-I ligands.

In the nucleus, BRRIAR lncRNA is expressed from and regulates an 11kb enhancer cluster found in ER+ breast cancer. The act of BRRIAR transcription is required for maintenance of the entire 11kb H3K27Ac mark while the BRRIAR RNA mediates the looping between the enh cluster and target gene, BHLHE40.

First paper of 2026! We started with 4 genetic variants from GWAS and ended with a potential lncRNA therapeutic for ER+ breast cancer. Spent hours with co-senior author @stacedw.bsky.social bouncing ideas around, discussing results and potential mechanisms. Loved every minute! rdcu.be/eXVnl

Great idea. Can you add me please.

I've been catching up on some reading and came across this paper. Ovarian cancers export a cancer-specific #lncRNA, Tu-stroma, to TME via exosomes. Tu-stroma alters spicing of flower gene in stromal cells to reduce cell fitness. Such a cool mechanism.

Join us in Keystone, CO, USA, for insights from Keynote Speaker V. Narry Kim at the Non-Coding RNA Biology conference. Register right up until the conference starts, on January 27th.

keysym.us/KSNCRNA25

#KSNCRNA25 #keystoneconferences #RNA #noncodingRNA #ncRNA #lncRNA

🫣 I'm guilty of this in my latest Molecular Cancer paper! Many of our lncRNAs don't have GENCODE IDs so we kept the XLOC_IDs from the output of our custom assembly. But this will get confusing as inevitably there with be the same XLOC_IDs for 2 different lncRNAs produced from different assemblies.

With respect to (b) I can't help but wonder if this was observed because only high expressing lncRNAs (>5RPKM) were selected for the screens. LncRNAs working in cis are much more likely to be expressed at lower levels than those working in trans.

We have two fully funded #Postdoctoral
positions:
-One dark genome explorer to lead a curiosity-driven project on #lncRNA
in #cancer #therapyresistance
-One experienced researcher interested in working on #drugdevelopment in collaboration with industrial partners
The links to apply below:

Australian researchers - I think we need to bring back #NHMRC grant review panels? What do others think?

I’m not on the committee anymore and I don’t think they have migrated over yet. 😖

Hi. Would you mind adding me to the lncRNA starter pack please 🙏🏻

Fellow #RNA lovers, please repost 🙏: 2 ERC-funded Post-doc positions are available in our lab to investigate #RNA structural ensemble and their dynamics in living cells. Application link: t.co/pYJ3H3j705

Lorne Genome

‼️Today is the last day to submit your Lorne Genome abstract for an oral presentation, your award application and to register at the earlybird rate‼️ If you've not already done so, time is running out. We look forward to seeing you in Lorne. lornegenome.org #lornegenome25

Could you add me to this starter please 🙏🏻 .

All good questions but not enough has been done in this area to answer them. There is some evidence of the formation of R loops which would confer specificity. Alternatively, the RNA could be inducing phase separation to concentrate TFs - doesn't account for the specificity though??

The lncRNA I’m working on is transcribed for an 11kb enhancer cluster. The RNA itself mediates the looping between the enhancer and the target gene and act of transcription maintains the 11kb H3K27Ac mark. The lncRNA also works in trans in the cytoplasm in the same pathway. Not just byproduct!

Hopefully see you there!

RNA Therapeutics Platform Manager

We’re hiring!🚨
The IRCM is seeking a Core Manager to lead its new cutting-edge #RNA Therapeutics Core. If you’re passionate about RNA and ready to develop future therapeutics, this is your chance! Join our dynamic team in Montreal

www.ircm.qc.ca/en/position-...